• Kuan-Chong Chao, Peng-Hui Wang, Chi-Ching Chang, Ming-Shyen Yen, and Chin-Wen Chi.
• Department of Obstetrics and Gynecology, Taipei Veterans General Hospital, Taipei, Taiwan, ROC. kcchao@vghtpe.gov.tw
• J Chin Med Assoc. 2013 Feb 1; 76 (2): 63-70.

BackgroundThe role of estrogen in the growth and survival of ovarian cancer cells is controversial. In this study, we investigated the changes in cell-cycle regulatory proteins in ovarian cancer cell lines after estrogen treatment to explore the role of estrogen in ovarian cancers.MethodsTwo ovarian adenocarcinoma cell lines were used for the study: the first, OC-117-VGH, was deficient in estrogen receptors (ER)α and ERβ, and the second, OVCAR3, was positive for ERα and ERβ. Serial concentrations of estrogen were used to evaluate the effects of estrogen on the survival of ovarian cancer cells. The cell-cycle regulatory proteins, including cyclin D1, cyclin E, p16/INK4a, and p27/KIP1, were used to check the possible mechanism of an estrogen effect on survival of the cancer cell line.ResultsEstrogen 0.01-1.0 μM inhibited the growth of both cell lines. There were no differences in cyclin D1 and E expression between the two cell lines after estrogen treatment, but the expression of p16/INK4a and p27/KIP1 was significantly higher in the OC-1170-VGH cell line than in the OVCAR3 cell line.ConclusionAlthough the ER-positive and ER-negative ovarian cancer cell lines were inhibited by estrogen, the influence of cell-cycle regulatory proteins was different between the two, suggesting that the inhibitory effect of estrogen on ovarian cancer cell lines might be mediated through different pathways.Copyright © 2012. Published by Elsevier B.V.

27 keywords...

hide…